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ABSTRACT 
Integrating Care: Evaluation of a Hepatitis C Clinic Co-located with Harm Reduction and 
Addiction Treatment Programs in a Rural Clinic 
Susan R. McKenrick, MSN, APRN, FNP-BC 
Background: West Virginia (WV) is second in the nation for cases of Hepatitis C Virus (HCV) 
per capita – meaning more than 24,000 residents are living with HCV. Most new cases are in 
young persons who inject drugs (PWID). However, the no-call, no-show rate for HCV patients 
coming to clinics in Morgantown is about 50%, indicating the need to do a better job engaging 
them in care. Literature suggests that integrating HCV clinics with harm reduction and addiction 
treatment programs increases uptake of HCV treatment. 
Objective: The overall objective was to establish an integrated HCV clinic where harm 
reduction and addiction treatment programs are offered to promote uptake of curative treatment 
by decreasing the number of no-call/no-show occurrences. 
Methods: A 12-week pilot study was planned with three aims for evaluation: 1) establish the 
clinic and evaluate rollout with an educational presentation pre/post-test and staff satisfaction 
survey followed by an implementation/feasibility survey near the end of the pilot 2) track and 
analyze the number of appointments made and kept using an Excel log to compare with other 
local clinics’ no-call/no-show rates 3) discover why patients historically have not kept 
appointments by use of a questionnaire. 
Results: Staff knowledge was significantly increased; the clinic was started; and staff 
satisfaction questionnaires returned exclusively positive results, as did implementation/feasibility 
follow-up surveys. There was a 10% decrease in the no-call/no-show rate. However, a national 
pandemic and seasonal constraint may have affected enrollment, leaving only one patient eligible 
to complete the survey.  
Discussion: While the clinic startup was successful, clinic attendance was low and reasons for 
lack of patient engagement remain largely unknown. However, the clinic is poised to further 
explore reasons for lack of engagement to halt the rising rate of HCV transmission in WV.
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INTEGRATING CARE  1 
Integrating Care: Evaluation of a Hepatitis C Clinic Co-located with Harm Reduction and 
Addiction Treatment Programs in a Rural Clinic 
The World Health Organization (WHO, 2017) has called for the worldwide elimination 
of Hepatitis C Virus (HCV) by 2030. Unfortunately, according to the Centers for Disease 
Control (CDC, 2019), the number of HCV cases in Appalachia, and specifically in West Virginia 
(WV), continues to climb as sequela to the current opioid epidemic that still has a firm grip in 
this state. Most new cases of HCV are in young people who inject drugs (PWID) – in particular, 
those who share needles with infected people (CDC). The problem is further complicated by the 
lack of HCV patient engagement in disease treatment. Anecdotal evidence from an HCV clinic 
held for four hours weekly in a local health department suggests a no-call, no-show rate of about 
50% (personal communication, April 2019), and a clinic held in the Infectious Disease 
Department of a nearby university affiliated hospital, reports a 70% no-show rate for new 
patients and a 30% no-show rate for follow-up visits (K. Burner, personal communication, July 
20, 2019). WV will only be able to meet the WHO’s challenge for elimination of HCV by 2030 
if providers and clinics implement a model of care that engages patients for HCV treatment and 
follow-up. 
Background 
HCV is a bloodborne virus that can cause systemic problems such as fatigue, coronary 
artery disease, endocrine diseases, depression, and more, as well as eventual liver damage that 
can lead to liver failure requiring transplantation, cancer, and death, according to the American 
Association for the Study of Liver Disease-Infectious Disease Society of America (AASLD-
IDSA, 2017). Because many of these symptoms are vague and not specific to any one disease, 
HCV often goes unrecognized and, thus, untreated – it has been dubbed “the silent killer” 
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(AASLD-IDSA, 2017). According to the WHO (2017) there are an estimated 71 million persons 
globally living with chronic HCV infections. It is estimated that 2.4 million people are infected 
with HCV in the United States (US; Hofmeister et al., 2019). And, although only 3,216 cases of 
acute (or newly infected) HCV were reported to the CDC for the US in 2017, given that many do 
not have symptoms, the estimates of actual number of acute HCV cases was closer to 44,700 
(CDC, 2019). It is worth noting here that, according to the CDC, up to 50% of acute infections 
will resolve spontaneously, without treatment. Most significant to WV is that between 2013 and 
2017, the rate of HCV in WV nearly doubled – from 3 .1 to 5.6 per 100,000 residents – making 
WV currently highest in the nation for new cases per capita (CDC).  
A report by the National Viral Hepatitis Roundtable (NVHR, 2019) reveals that 
approximately 20,600 West Virginians are chronically infected with HCV and the population at 
greatest risk is young people who inject drugs (NVHR). Because there is stigma attached to 
PWID, there is also to HCV, as well as fear of being reported to authorities for using illegal 
substances. Many of those using injection drugs are either uninsured or have Medicaid as their 
primary insurance (NVHR) making it difficult, if not impossible, to obtain treatment for their 
illness. Homelessness and lack of steady employment further complicate their situations. Also 
complicating treatment and cure are the restrictions imposed by WV Medicaid (which influences 
the policies of many commercial insurers) including a 3-month sobriety requirement and that the 
prescriber for the curative medications must be a specialist such as gastroenterology, infectious 
disease, or hepatology (NVHR). Until October 1, 2019, a liver fibrosis score of F2 or greater 
(indicating liver damage had already occurred) was also a requirement to approve treatment- that 
restriction has been removed (State Of WV Department Of Health and Human Resources 
[WVDHHR]; Bureau For Medical Services, 2019). The cost of the oral direct acting antiviral 
INTEGRATING CARE   3 
 
(DAAs), medication which can cure HCV, begins at around $20,000 (NVHR) for the course of 
treatment. It is not feasible for most of the affected population to pay out-of-pocket for curative 
treatment. Co-pays for office visits and lab/radiology studies can also be cost-prohibitive. 
Reported WV Medicaid costs for treating HCV totaled more than $27 million between 2014 and 
2016 (WVDHHR, 2019). 
Problem Statement 
 Worldwide elimination of HCV by 2030 is a WHO goal (WHO, 2017); but, with 
appointment no-call, no-show rates at HCV clinics in Morgantown ranging from 30 – 70%, and 
approximately 20,600 West Virginians needing HCV treatment, it is time for healthcare 
providers in WV to change how this population is reached to meet their needs more effectively. 
Significance of the Problem 
In April of 2019 one of two HCV clinics in Morgantown (staffed by the author) closed 
due to an average no-call/no-show rate of 50% that resulted in a low patient volume. Another 
clinic in Morgantown associated with infectious disease at West Virginia University (WVU) 
hospitals has a higher patient volume – approximately 1000 patients over the past 3.5 years 
drawing from WV, OH, and PA – but reports a 70% no-call/no-show rate for first time visits and 
30% for follow up visits, which reflects a similar 50% average no show rate (K. Burner, personal 
communication, July 20, 2019). However, nearly 20,600 West Virginians with HCV makes 
patient engagement an imperative. 
Purpose of the Project 
 The overarching purpose of this project was to increase the number of people living with 
chronic HCV who are treated and cured of this potentially life-threatening illness by making care 
and treatment more accessible to the population most vulnerable – PWID. Studies have shown 
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that by integrating services (HCV, harm reduction, and addiction treatment), patient engagement 
is increased (Batchelder et al., 2015; Burton et al., 2019; Butner et al., 2017; Fragomeli & 
Weltman, 2015; Treloar et al., 2013), so it follows that the no-call, no-show rate will decrease.  
Significance of the Project 
 Unfortunately, despite the WHO’s (2017) charge, the number of HCV cases in 
Appalachia, specifically in WV, continues to climb as sequela to the current opioid epidemic that 
still has a firm grip in this state (CDC, 2019; NVHR, 2019). Most new cases of HCV are in 
young PWID – particularly those who share needles with infected people (CDC, 2016). This 
problem is further complicated by the lack of HCV patient engagement in care for this disease, 
as evidenced by the high no-call, no-show rates in two local HCV clinics. WV will only be able 
to meet the WHO challenge for elimination of HCV by 2030 if providers and clinics implement 
models of care that engage patients for HCV treatment and follow-up. 
Review and Synthesis of Literature 
 An initial non-exhaustive literature review was performed driven by a clinical question 
using the Population, Intervention, Comparison, Outcome, Time (PICOT) method (Melnyk & 
Fineout-Overholt, 2015): In patients with HCV and coexisting substance use disorder (SUD), 
how does integrating and HCV clinic within a clinic offering harm reduction and addiction 
treatment programs, compared to separate appointments at another location/clinic increase the 
number of patients who engage in care for HCV treatment over 3 months? Using 
EbscoHost/CINAHL, Clinical Key, and WVU Libraries “All Databases” function, the Cochrane 
database was searched separately, and all included the keywords HCV, Hep C, integrated 
treatment, opioid treatment, and HCV treatment. After removing exact duplicates, limiting to the 
last 5 years, English language, and peer reviewed – the search yielded 716 results. Inclusion 
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criteria was defined as: a) HCV clinics that were integrated within opioid substitution treatment 
clinics, b) they were community-based clinics, and c) treatment was with DAAs, and exclusion 
criteria defined as a) HCV treatment with older regimens that included ribavirin, interferon, or 
other treatment than all-oral DAAs, b) residential treatment settings, c) no integration with harm 
reduction or addiction treatment programs were then applied. After reviewing 75 abstracts, 11 
applicable publications were included in the review. 
Several studies (Batchelder et al., 2015; Burton et al., 2019; Butner et al., 2017; Treloar 
et al., 2013) indicated integrated treatment for HCV and drug use is effective in increasing 
engagement and follow-up for testing and treatment, citing reasons such as trust in providers, 
less stigmatized, and a non-judgmental atmosphere. A retrospective study by Stein et al. (2012) 
reported effectiveness of concurrent group treatment (CGT) within a methadone maintenance 
program. A systematic review by Pourmarzi et al. (2018) investigating community-based 
treatments (including one multidisciplinary model) reported several positive findings, such as 
trust in providers and increased accessibility, and suggested integrated services should be further 
considered. However, Rance and colleagues (2012) suggest in their study that integration may 
further stigmatize this already marginalized population. 
Batchelder et al. (2015) studied psychological and behavioral changes in SUD patients 
(both current and former) in a primary care clinic (treating HCV) with an integrated methadone 
clinic. This qualitative study with 31 participants concluded that an integrated model of care has 
the potential to increase patient engagement in care by reducing patient perceptions of stigma 
and shame related to HCV and substance use. The study further concluded that the efficacy of 
the concept may have been rooted in their group treatment program wherein there was support 
for the shared experiences of interferon therapy-related side effects (a possible limitation of the 
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study in relation to the current project as only DAA therapy is offered). Another limitation was 
convenience sampling. While the purpose of the study was not in alignment with the current 
project, the author believes it lends support for HCV clinic integration as a way to increase 
engagement in care.  
Burton et al. (2019) demonstrated efficacy in integrating HCV care in a residential drug 
treatment program for Veterans. The study took place in an academic affiliated VA medical 
center with a 15-bed, rolling admission SUD treatment program. The facility serves a cross-
section of African American (64%), White (35.4%), and Hispanic (0.6%) Veterans, 54% of 
whom are homeless. Many of the clients have psychiatric conditions including depression, post-
traumatic stress disorder, and nearly 10% with a significant mental illness such as schizophrenia 
or bipolar disorder. The average length of stay was four weeks. In this setting, the SUD clinic 
and infectious disease clinics are located near one another, though on different floors of the main 
hospital. When SUD patients were discharged, a follow up program was implemented – every 
two weeks for those already on HCV treatment, phone calls and letters for those who missed 
appointments, and 3-6-month intervals for those waiting to begin treatment. All patients of the 
SUD program were offered HCV testing and provided with HCV education (for treatment as 
needed and prevention if not infected). The results revealed that uptake in initiation and follow 
through to completion of HCV treatment increased with the integrated model of care. Of the 597 
patients screened for HCV, 74 were diagnosed with the virus and 53 were appropriate for 
treatment. Of these, 48 (77.59%) completed treatment. 
There were notable limitations to the Burton et al. (2019) study. First, a threat to internal 
validity was the lack of comparative data, making it difficult to determine if there was significant 
improvement in uptake of treatment and follow up. Additionally, the study occurred in a VA 
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facility where there are no treatment restrictions imposed, as in many state Medicaid programs 
(NVHR, 2017), therefore decreasing the ability to generalize results to the other populations, 
thus jeopardizing external validity. Despite these limitations, the study supports a clinical shift to 
integrating HCV care with addiction treatment to increase patient engagement. 
A subsequent search was performed substituting “opioid treatment” with “harm 
reduction” in the keywords. Again, using EbscoHost/CINAHL, Clinical Key, and WVU 
Libraries “All Databases” function, as well as a separate Cochrane database search, the search 
yielded 2,921 results. However, after applying the same inclusion and exclusion criteria, only 
three studies were applicable. Two additional studies were included as a result of the 
“snowballing” search technique for a total of five more studies included in the final review. 
The Brener group (2013) is discussed in further detail below and provided the most 
compelling support for connecting HCV treatment and harm reduction. However, in this study, 
the harm reduction program was across the street from an HCV clinic and had an established  
referral system as a means of engaging patients for the HCV clinic (Brener et al.). Furthermore, 
the work actually falls outside the five-year inclusion criteria parameters in an attempt to exclude 
studies involving older treatment therapies prior to the advent of all-oral DAAs. Regardless, their 
conclusions were enlightening in that an accepting, non-judgmental atmosphere of the clinic 
itself that was the noted as key to its success (Brener et al.). Bruggmann and Litwin (2013) 
provided a commentary on several models and settings for HCV and concluded that no single 
approach is best for all patients with HCV and suggest that there is certainly room for 
exploration of innovative models. The work by Kishore et al. (2019) was included for its 
perspective on integration with harm reduction programs as key to success and stigma as a 
critical barrier to engagement in treatment. Stigma as a barrier is significant in that the primary 
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source of transmission is currently shared needle use among PWID, a stigmatized population 
(CDC, 2016). Milne et al., (2015) and Morris et al., (2017) both support the concurrent harm 
reduction program and HCV clinic model as an effective way to increase patient engagement in 
care and curative treatment.  
 Utilizing mixed methods, the Brener group (2013) evaluated a dedicated HCV clinic 
located across the street from a harm reduction program to easily capture referrals from the 
program. The clinic was defined as “integrated” and described as “holistic” and included a staff 
of nurses, managers, counselors, case workers, general practitioners, academics, a consultant 
physician, and a receptionist. In all, 24 staff members and 24 clients participated in the 
investigator-led interviews. Through interviews, the researchers discovered that supportive, non-
judgmental relationships between clients and providers were key to the success of the clinic. 
Clients and providers articulated that a holistic approach to care was central to improved 
outcomes (HCV treatment, symptom management, as well as general health needs). Clients were 
enabled to overcome a variety of barriers to care, such as fear of discrimination, feelings of 
stigmatization. Unfortunately, an earthquake destroyed the clinic and much of the data of the 
quantitative component of the study prior to the completion of the study.  
 A significant limitation of the work by Brener et al. (2013) is the fact that treatment was 
not administered in the clinic; patients were referred to the local hospital for treatment, so 
definitions of both internal and external validity are in question as there is no comparison group 
to measure improvement against and no statistical results are presented in the work.  
 Bruggmann and Litwin (2013) reviewed seven effective integrated models of care for 
HCV (including integration into addiction treatment and general practice, with community-based 
opioid substitution treatment, general practitioner-based models, integrating HCV in secondary 
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and tertiary settings, direct observation therapy, and peer-based models). They concluded that 
any of these models requires good collaboration of providers, a nonjudgmental attitude among 
providers, and an elevated level of acceptance of the patients’ life circumstances. While it was 
not a systematic review with statistical analysis, the literature cited supported each model 
(several of which are used in the current project). 
 Using a case study, Milne et al., (2015) describe how an integrated model of care, where 
HCV care was co-located with harm reduction and addiction therapy, as well as many other 
services, in an inner-city clinic, engendered trusting relationships, which the authors cite as 
“central” to enhancing engagement in HCV care and treatment. Over a two-year period, from 
2012 through 2014, the clinic grew from 83 to 705 HCV Registry patients, and treated 101 
patients with an interferon regimen during the same time period, achieving an average sustained 
virologic response (cure) of 81% (Milne et al., 2015). Although a case study, the Milne work 
adds more weight to the growing body of literature. In addition, study findings cited support 
issues presented in the current project, deeming the Milne group work relevant. 
 Overall, 10 of the articles reviewed support an integrated model of care and one suggests 
that it may actually increase stigma. There is a small, but strong body of literature to support a 
shift to an integrated model of care for HCV in the US; however, the search for supporting 
literature yielded primarily studies from other countries, particularly the UK and Canada. Even 
so, integrated clinics, such as the Evergreen Clinics, a small network of primary care clinics in 
Buffalo, NY (Evergreen Health, 2019) that treat SUD as well as HCV do exist. Therefore, it is 
reasonable to assume that such a model may be successful in WV, where the number of infected 
patients is increasing in direct relation to the state’s opioid epidemic (CDC, 2017).  
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 In February of 2020, a final literature search was performed using the same keywords and 
returning two additional articles appropriate for inclusion related to the topic. While neither is a  
research project offering data on integrating HCV care with harm reduction and addiction 
treatment, each offers valued information on the subject. Hoj et al. (2019) present a theoretical 
framework for study and care of the PWID population. The authors observed that uptake of 
treatment had not increased as expected as insurance restrictions to treatment in Canada (which 
reflected those still imposed in many states in the US) were removed. They questioned why there 
was an apparent gap in care and believed there was a need for “deliberate” theory to support 
research and direct the delivery of care to PWID. Interestingly, this group also utilized 
“candidacy”, among other theories and frameworks, to shape their own framework; the final 
product is built squarely on the theory of candidacy. 
An editorial by Marshall et al. (2019) emphasizes the need to change the approach to care 
of HCV patients who inject drugs. They suggest not only integrating care in terms of location, 
but in terms of care provider – recommending that addiction medicine specialists are well-poised 
to facilitate care of HCV in PWID as part of their addiction treatment programs. Although one of 
the authors (Treloar) disclosed a conflict of interest (paid speaker’s bureau), the emphasis of this 
article is the integrated care model. Both writings support integrated models of care and 
treatment and therefore were included in the current review.  
Theoretical Frameworks 
 Two frameworks were chosen to direct this project – Roger’s Diffusion of Innovations 
and Candidacy. Rogers (2003) explains that Diffusion of Innovations is about the way a new idea 
is communicated to others and perceived by others. According to Rogers, an idea may or may 
not necessarily be “new”, as in never thought of before, but it becomes “new” as someone has a 
INTEGRATING CARE   11 
 
new awareness of it with a plan to put it into action because the status quo is not working. The 
Candidacy framework, as presented by Tookey et al. (2018) speaks to an individual’s sense of 
worth or eligibility of treatment for an illness and suggests six stages that may be involved are a) 
Identification of candidacy b) Navigation of services c) Permeability of services d) Appearance 
at services e) Adjudication by healthcare f) Offers of and resistance to services. How these 
frameworks support the project is discussed later. 
Project 
Evidence-Based Project/Intervention Plan 
 The project intervention involved strategically integrating an HCV clinic within a local 
free primary care clinic, Milan Puskar Health Right (MPHR), that offers both a harm reduction 
program and addiction treatment. The overarching goal is to increase engagement in care by 
those infected with HCV by locating the clinic in an environment where the population at highest 
risk for HCV (PWID) would feel comfortable and welcomed. The hours of operation for the 
clinic coincided with the harm reduction program held on Friday afternoons from 1:00 PM until 
4:30 PM. The timing offers two benefits: 1) Patients who are already coming for the harm 
reduction program are able to schedule appointments for HCV care without making an extra trip 
to MPHR and 2) Clients of the harm reduction program who are screened and test positive (via 
rapid testing) can be introduced to the provider to establish an immediate therapeutic relationship 
which will promote active engagement in care (appointments made and kept.)  A Nurse 
Practitioner (the author), who has trained extensively in HCV treatment and regularly attends 
Project ECHO (Extension for Community Healthcare Outcomes) HCV programming for 
continuing support, is the care provider for the clinic. The project received WVU Internal 
Review Board (IRB) approval in mid-January. The author had been working closely with key 
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staff at MPHR, so the clinic was prepared for almost immediate startup upon IRB approval. The 
plan was for the clinic to be held and data collected for 12 weeks. Planned data collection 
included a deidentified patient questionnaire to discover themes for lack of engagement in care 
(Appendix A) and a deidentified Excel log to track appointments made, kept, cancelled, 
rescheduled, and no-call, no-show (Appendix B). 
Theoretical Frameworks Discussion 
 The status quo for HCV treatment is primary care, infectious disease specialty, or 
gastroenterology. According to Rogers (2003), there are five phases an innovative plan to change 
or improve on the status quo goes through – knowledge, persuasion, decision, implementation, 
and confirmation. It was during the “knowledge” phase it became clear that the current HCV 
clinic was not well attended at the Health Department and the idea was born to integrate HCV 
care with drug addiction treatment. After an initial plan to integrate the clinic into a local 
addiction treatment center was found to be unfeasible, the author continued to pursue other 
options, leading to the opportunity to integrate HCV care with harm reduction services and 
addiction treatment. The “persuasion” phase occurred when a review of literature affirmed 
placing the clinic where it would be more easily accessed by those at the highest risk – those who 
are injection drug users. The “decision” phase is when the choice to adopt or reject a new idea – 
in this case, to adopt – is made. This phase includes buy-in from stakeholders. When the author 
approached MPHR key administrative personnel about integrating an HCV Clinic with existing 
harm reduction and addiction treatment, the response was unreservedly positive. 
“Implementation” is the next phase where a new idea is put into action and outcomes are 
measured to see if it is effective. January 17, 2020 was the first day of clinic. Finally, the plan 
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itself is confirmed or adopted - either it works and continues, works but needs adjusted, or did 
not work and is abandoned.  
 The Candidacy framework, as presented by Tookey et al. (2018) speaks to an individual’s 
sense of worth or eligibility of treatment for an illness and suggests six stages that may be 
involved are: 
• Identification of candidacy - is the patient eligible, do they even know they need care? 
Do those infected with HCV know there is a cure? HCV has been referred to as a “silent 
killer”. Those who are infected often do not realize they have the disease as symptoms 
can mimic other diseases and damage to the liver may not be realized for many years 
after exposure.  
• Navigation of services - what is their health literacy, can they identify and reach the 
proper services? Meeting patients where they are, in a non-threatening environment 
where they already access other services will mitigate the problem of poor health literacy 
and uncertainty of where to get help for this disease. 
• Permeability of services - do they feel stigmatized or discriminated against, and is the 
environment hostile or uninviting? Literature suggests that the stigma of HCV inhibits 
use of mainstream services (Treloar et al., 2013). Holding the clinic where they are 
already accessing primary care, addiction treatment, and harm reduction services lessens 
those feelings.  
• Appearance at services - are patients able to effectively communicate their needs to 
providers? HCV symptoms can be vague and mimic other conditions, so patients may 
need prompted to elicit an accurate picture of their current health status.  
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• Adjudication by healthcare - are providers following the care guidelines or does personal 
bias interfere? The new DAA medications are expensive and insurers have been 
reluctant to provide coverage if patients infected with HCV have no liver damage yet or 
are still injecting drugs. Thankfully, many insurers have begun to lift these restrictions, 
along with the specialty provider/consult requirement.  
• Offers of and resistance to services - do patients fully understand their treatment options, 
the costs, and other treatment-related issues or do they resist offers for testing and 
treatment out of fear or lack of knowledge? Patients are not always aware of the newer 
oral DAA curative treatments for HCV or they do not realize the side effect profile is not 
severe like people they may know had treatment with interferon and/or ribavirin, so they 
avoid treatment out of fear of the side effects that they have heard about.  
These stages and concepts are the framework for understanding this patient population’s 
particular need to be treated for HCV in a non-judgmental, compassionate, friendly environment 
where education is provided about how to take care of themselves and their loved ones, prevent 
transmission of the disease, and the treatment options that are available to cure the virus. 
Feasibility Analysis 
With approximately 20,600 West Virginians infected with HCV (NVHR, 2019), more 
HCV clinics are needed, not fewer. This quality improvement project was aimed at increasing 
patient engagement by establishing an integrated HCV clinic within a local free clinic, coincident 
with harm reduction and opioid addiction programs to improve ease of access to HCV care. 
Studies have shown that integrated HCV and addiction treatment show an increase in patient 
engagement in care (Batchelder et al., 2015; Burton et al., 2019; Butner et al., 2017; Treloar et 
al., 2013) – further strengthening the presence of the HCV Clinic at MPHR.  Meetings with the 
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executive director, nursing director, and author began in late August of 2019 to discuss plans for 
the HCV Clinic. These meetings culminated in a signed letter of support for the project from the 
executive director of MPHR (Appendix C).  
Looking ahead at sustainability – steps have already been taken for the author to become 
credentialed to be able to bill for services pending negotiation of a WVU clinical faculty practice 
site allowing the author (who is a WVU School of Nursing faculty) to continue the work. 
The author has developed an HCV protocol checklist for other/new providers to follow 
and will continue to revise and share this as needs arise (Appendix D). Opportunities for 
expansion at MPHR include having a clinic that runs concurrent with the Wednesday harm 
reduction time. They also have a mobile harm reduction unit that may have potential for reaching 
other counties. Ideally, WV Medicaid would remove the current restrictions to treatment so that 
primary care providers can treat all uncomplicated patients without referral to specialty 
providers, paving the way for all providers at MPHR to become educated and confident to treat 
HCV as an integral part of primary care. The author developed a policy brief to share with key 
stakeholders at WV Medicaid with the intent to affect a change in policy that would remove 
HCV treatment restrictions. In the long term, if the WHO (2017) goal of complete elimination by 
2030 is met, the clinic would hopefully then become obsolete.  
Impact Analysis 
 The primary expected impact will be an increase in the number of people with HCV who 
are treated and cured of the disease. Integrating the HCV clinic with harm reduction services 
means the clinic will have greater visibility to the population at highest risk for the disease. If 
this pilot is successful and the model is imitated elsewhere, it could contribute significantly to the 
WHO goal of worldwide elimination of HCV by 2030 (WHO, 2017). As much of what is written 
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on a model where HCV care coincides with harm reduction services and/or addiction treatment 
comes from abroad, there is opportunity to publish this work, as well as writing to inform other 
healthcare providers with similar no-show rates of an innovative effective model of care to 
implement in the US. It is said, “Success Breeds Success” – to those who are passionate about 
bringing curative treatment to HCV patients and are in search of innovative ways to capture this 
population, success of this pilot project may be attractive. 
Resources 
 Personnel needs. Upon discussion with administrative personnel at MPHR prior to clinic 
startup it was determined that the current staffing level for Friday afternoon was adequate to 
manage any additional patient needs generated by the clinic, including check-in, rooming, and 
lab draws. Clinic staff present on Friday afternoon includes an RN, LPN, two medical assistants, 
and a receptionist. No additional personnel were required for clinic the function.  
 Budget. The total anticipated amount needed for this project was $3,275. At the time the 
budget was developed, the author hoped to obtain a grant from the West Virginia Clinical & 
Translational Science Institute (WVCTSI); however, the timing for grant submission/award did 
not coincide with the project timing and the grant was not pursued. Funding for the project came 
through donations. The actual cost of clinic implementation was $3038, which was $207 under 
budget and $32 under the total income allotted for the project. The budget balance sheet with 
explanations is presented in Appendix E. 
 Technology. MPHR has several laptop computers available for provider use to chart 
using a web-based electronic health record (EHR). The author was named on the EHR license as 
a provider at no additional cost to the organization. No further technology needs were identified 
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during the pilot period, apart from the author’s laptop to track appointments using an Excel 
spreadsheet and IBM SPSS software to calculate test statistics for project evaluation. 
Congruence of Organization’s Strategic Plan/Mission to Project 
 Milan Puskar Health Right's Mission Statement:   
Health Right is a primary care clinic that provides health care at no 
cost to uninsured or underinsured low-income residents of North 
Central WV. Health Right promotes health through direct service, 
education, and advocacy. 
The mission of MPHR aligns with the goals of this project well. Housed in MPHR is a syringe 
access/harm reduction program known as the LIGHT program. LIGHT is an acronym for Living 
In Good Health Together. Shared needles by PWID is the primary transmission route for HCV in 
WV today (NVHR, 2017). Timing the HCV clinic to run concurrently with the LIGHT program 
could minimize fear of stigma, promote patient trust, and improve access to care. MPHR 
currently hosts several other specialty clinics such as women’s health, diabetes care, and HIV 
testing, in addition to mental health services, homeless services, addiction treatment, and primary 
health care. The founding premise of MPHR is that every person has a right to health care 
regardless of their insurance status or ability to pay (GuideStar, 2017). The purpose of the project 
is to increase the number of people cured of HCV in WV, and currently the population at greatest 
risk is people who inject drugs – many of whom are either uninsured or underinsured. The 
project is also in line with WVU’s mission, vision, and values of service to the community and 
state as a land-grant institution.
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Evidence of Key Site Support 
 A letter of support was obtained by the director of MPHR and is included as an appendix 
item as noted previously. Positive, welcoming attitudes and helpfulness of the staff at MPHR 
were also evidence of their support for integrating the HCV Clinic.   
Measurable Project Objectives 
The overarching goal of the project is to increase patient engagement in care for HCV. To 
that end, the three aims to evaluate this project were to 1) establish an integrated HCV clinic at a 
MPHR to run concurrently with their LIGHT program on Friday afternoons, 2) evaluate the 
efficacy of the plan, and 3) explore the reasons patients miss appointments.  
Aim 1. Establishment of the HCV clinic at MPHR was measured through three 
objectives. First, completing a checklist of items to carry out for the creation of the clinic. The 
checklist was kept simple and is found in Appendix F. All checklist items were developed to 
ease assimilation of the clinic into the current workflow. Each was accomplished prior to the first 
patient care day. Second, a “Lunch and Learn” educational program, attended by a mix of 
APRNs, RNs, MAs, social workers, counselors, and office staff,  took place two days prior to the 
first clinic day was evaluated using a pre/post-test (Appendix G) taken by all 15 attendees prior 
to and following the program. An anonymous staff satisfaction evaluation survey (Appendix H) 
was also used to evaluate the program. Using IBM SPSS, a paired-samples t-test was planned to 
evaluate the impact of the educational presentation on staff knowledge of HCV care and 
services.  
A third objective, concerning implementation/feasibility, was added later to the pilot with 
an IRB amendment to enhance the evaluation of clinic startup. An anonymous survey (Appendix 
I) was administered via Qualtrics near the end of the 12-week pilot period to assess MPHR staff 
perception of the value, need for, and rollout of the clinic. Development of the survey was 
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guided by Bowen et al. (2009) where eight areas of focus for feasibility studies were identified. 
The areas this survey focused on were acceptability – evaluated by satisfaction and intent to 
continue use, demand – evaluated by fit within the organizational culture, implementation – 
measured by degree and success or failure of execution, practicality – measured by the efficiency 
and quality of implementation, integration – measured by the perceived fit with existing 
infrastructure and perceived sustainability, expansion – measured by fit with organization goals 
and culture and/or positive or negative effects on organization, , and limited efficacy – measured 
by maintenance of changes from initial change.  
 Finally, clinic startup was evaluated periodically using the Plan-Do-Study-Act (PDSA) 
method as described by the Institute for Healthcare Improvement (IHI, 2020). PDSA cycles have 
been developed as a methodical system for making and evaluating changes on a small scale 
(IHI). PDSA cycles directed improvements over the course of the project (IHI).  
Aim 2. The planned evaluation of efficacy of the intervention to increase engagement in 
HCV care was to maintain a deidentified Excel log (Appendix B) of appointments made, kept, 
called to cancel, called to reschedule, or no-call/no-show and compare findings of no-call, no-
show rates at two other clinics in Morgantown (one hospital-based, one located at a health 
department). 
Aim 3. The third aim was to discover reasons for the lack of engagement in care among 
HCV patients using a Likert survey style questionnaire (Appendix A) with a list of 15 possible 
reasons for missed appointments such as transportation problems, forgot, fear, dissatisfaction 
with previous care/treatment to value on a scale of 1-5 how significant the items were with 1 = 
Not at all and 5 = A lot. A text option was included to write in reasons not listed. There was also 
a free text question to elicit what, if anything, the healthcare system could do to help them keep 
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their appointments. Descriptive statistics were planned to reveal if a trend toward any reason/s 
existed. Such information could then be used to explore ways to mitigate appointment barriers. 
Any demographic data obtained would enrich the main project findings.  
Results 
Aim 1. The clinic startup checklist of items to accomplish prior to the first patient day 
helped ensure that the staff and provider were prepared with the proper paperwork, supplies, 
equipment, credentialing, and general readiness. The objective of increasing staff knowledge 
about HCV was met through the educational “Lunch and Learn” program. Providing a light 
lunch for participants helped create a warm learning environment. There was a significant 
increase in the Staff Education test scores from pre-test (M = 5.13, SD = 1.13) to the post-test (M 
= 6.67, SD = 0.62), t (14) = -5.996, p=<.001 (two-tailed). The mean change in scores was -1.53 
with a 95% confidence interval ranging from [-2.08 to -.98]. The four-question Likert survey 
designed to evaluate staff readiness and confidence was completed by 11(73%) attendees. The 
scale ranged from 1 = Very satisfied to 5 = Very dissatisfied. For item 1 – The educational 
program helped me feel prepared for this clinic – the mean score was 1.09 (SD = .302), for item 
2 – The Phone Triage flyer helped me answer questions when patients called – the mean was 
1.09 (SD = .302), the third item – The education program helped me feel more confident about 
using patient assistance programs for HCV medications – had a mean of 1.18 (SD = .405), and 
the final item – The learning objectives (disease process, fielding phone questions, anticipated 
lab and imaging tests, and assistance programs) were met – had a mean of 1.09 (SD .302).  
There were 13 respondents (n =13) to the implementation/feasibility survey including 11 
females and two males with the average age  range 35 to 45 years old. Sixty-two percent (62%) 
of the respondents had worked at MPHR for less than two years, 23% 2-4 years, and 15% longer 
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than six years with 85% of the respondents being full time employees and 15% part-time. The 
participants were a mix of nursing staff, office staff, providers (MD, PA, NP), case 
managers/social workers, and “others”. Ten (80%) of the 13 attended the prestart “Lunch and 
Learn” session. The remaining items were based on a Likert scale of 1 = Strongly agree, 2 = 
Somewhat agree, 3 = Neither agree nor disagree, 4 = Somewhat disagree, 5 = Strongly disagree, 
and a sixth option = Not applicable. The results shown in Table 1 indicate the staff’s perceived 
need and support for clinic.  
The Plan stage of the cycle (plan for change) led to clinic readiness for the first patient 
day on January 17, 2020. In the Do stage, the clinic began seeing patients on a small scale with 
one – two patients scheduled per clinic session. In the Study phase the author noted what worked 
well and what did not regarding workflow and referral, which led to changes in lab testing 
ordered by primary care providers who expressed some confusion about the algorithm for 
testing. In the Act phase a  new, clearer algorithm was developed and made available to all 
MPHR providers by posting in the providers’ workroom. The author elicited provider feedback 
over the next couple of weeks of clinic and all expressed satisfaction with the improved testing 
algorithm. No other issues were identified with subsequent PDSA cycles. 
Aim 2. Over the nine weeks that the clinic was able to see patients, seven were 
scheduled, two patients were seen, two did not call/show for their appointments, one cancelled 
by phone, two other patients were found to have cleared the virus spontaneously and were 
notified by their primary care providers of this finding and were removed from the schedule for a 
final n = 5. While this is a small sample, there is some evidence of efficacy in that there was only 
a 40% No-call/No-show rate during this time as depicted in Figure 1 and Table 2. Weather 
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affected the clinic throughout the winter, and the onset of the COVID-19 pandemic disrupted the 
final weeks of the project. 
 Aim 3. Of the two patients seen in clinic, only one qualified to complete the 
survey exploring reasons for missed appointments. The second patient had been seen by a 
volunteer prior to IRB approval for the project and was there for treatment follow-up. However, 
some of the answers on the survey collected support the reasons for establishing this clinic – a 
score of 3 was assigned to “Felt judged or discriminated against” and  5 for “Fear”. Other 
reasons included “Forgot” and “Copay was too high”, which were both scored a 4. Concerns 
written in the “Other” box included the cost of the medication and concern that re-treatment 
would not be an option if infected again. Although survey data was only available from one 
patient, an “n of 1” in clinical care/quality improvement may be a useful starting place to begin 
to understand complex issues affecting this challenging population.  
Discussion and Recommendations 
 The theoretical frameworks of Diffusion of Innovations (Rogers, 2003) and Candidacy 
(Tookey et al., 2014) supported this project well. While much is written about this model in the 
UK and Australia, (Batchelder et al., 2015; Burton et al., 2019; Butner et al., 2017; Treloar et al., 
2013), there is little about it in the US. Adopting this care model and reproducing it in WV has 
the potential to impact the broader US population as it moves toward elimination of HCV. The 
Tookey group (2014) Candidacy framework guides providers to ask good questions and be 
sensitive to the unique needs of the population at greatest risk for HCV – PWID. For example, an 
older patient may have had treatment prior to the new DAAs and not be aware that there are new 
drugs in pill form, taken once daily for eight to twelve weeks that have few side effects. That 
patient may be reticent to begin treatment based on past experience and lack of knowledge – they 
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may be resistant to services (the last stage of Candidacy). Sensitive providers can overcome the 
resistance with education and counseling to guide patients toward readiness for treatment.  
The post-test analysis showed a significant increase in staff knowledge about HCV and 
the functions of the clinic over the pretest; however, they may have benefited from further 
discussion of the disease progression, and more in-depth discussion of a testing to treatment 
algorithm – particularly for care providers as there were lingering questions about what labs to 
order and when. It might have been better to hold two sessions – one for clinical staff and one for 
providers as each group had discreet questions and needs. The PDSA cycle revealed the lab 
testing algorithm issue so it could be remedied quickly.  
 As previously noted, weather and the onset of the COVID-19 may have been a factor in 
patient referrals and appointments as MPHR was shifting to seeing only urgent needs patients 
(which would not typically include HCV patients). Further impacting the case load was that a 
few more patients that providers had planned to refer were found to have spontaneously cleared 
the virus when lab tests in preparation for referral was obtained, so there was no need to refer. 
Despite this, the no-call/no-show rate was shown at 9 weeks of clinic to be 40% (as previously 
discussed, see Table 2 and Figure 1).  
Another possible barrier for this clinic is the time frame. The clinic is only held once per 
week on Friday afternoons, which could conflict with work or other schedules. Expanding to 
include other appointment options may help increase attendance. The LIGHT harm reduction 
program has a mobile unit that serves other counties which may have potential for screening and 
HCV clinic referral. Another option might be to make the clinic schedule flexible – meaning that 
the clinic is open from 1-4:30, and HCV patients can come at the time most convenient for them. 
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The mobile unit and flex scheduling options are novel approaches that were not noted in the 
literature reviewed for the project.  
 The project should be continued (in fact, there was concern expressed by staff about what 
was to happen to the clinic at the end of the pilot), becoming part of the clinic standard of care 
for PWID who also have HCV. MPHR providers see patients with HCV often. Establishing a 
trusted presence is key to growing the clinic. Key stakeholders in the clinic – the director, staff, 
providers – have expressed verbally and by survey responses that they believe in the value of an 
HCV clinic on site. The clinic holds potential for further study to hone in on reasons this 
population tends to have a high no-call/no-show rate, as well as demonstrate the efficacy of an 
integrated clinical model of care by the volume of patients over a longer period.  MPHR is well 
suited for continuation and should serve WV well as a model for HCV care.  
Conclusion 
 Although the clinic startup was successful, and staff HCV knowledge improved, clinic 
attendance was minimal and additional reasons for lack of patient engagement remain unknown. 
With time to establish a trusted presence with the patient population, warmer weather, abatement 
of COVID-19, and increasing referrals from the MPHR primary care providers, the integrated 
model of HCV care there has the potential to set the pace for similar models across the state. The 
clinic is poised to explore and improve care engagement in hopes of halting WV’s and the 
nation’s rising HCV transmission rate. 
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Attainment of the Essentials of Doctoral Education for Advanced Practice 
 The eight Essentials of Doctoral Education for Advanced Practice are specified learning 
outcomes and objectives put forth for DNP students by the American Association of Colleges of 
Nursing (ANCC, 2006).  
Essential I: Scientific Underpinnings for Practice was met using two theoretical frameworks 
to support the clinic integration and qualitative research to explore reasons for lack of 
engagement in care among PWID who have HCV.  
Essential II: Organizational and Systems Leadership for Quality Improvement and 
Systems Thinking objectives were met through the development and implementation of this 
project - a care delivery approach was found lacking, but, through communication with Health 
Right leadership, a plan to improve delivery of health care to hep c  patients was developed. The 
project required a feasibility and needs assessment study and the development of a budget. 
Finally, the project demonstrates sensitivity to an organizational culture that is already sensitive 
to the targeted population.  
Essential III: Clinical Scholarship and Analytical Methods for Evidence-Based Practice 
were met through performing a literature review and using the information to support a systems 
change in the way the needs of HCV patients are met. The creation and implementation of a 
qualitative interview/survey to explore the reasons for missed appointments in this population, a 
quantitative data analysis of appointment no-call, no-shows compared to two other area Hep C 
clinics, and dissemination of these findings through project presentation and publication will 
complete this DNP essential.  
Essential IV: Information Systems/Technology and Patient Care Technology for the 
Improvement and Transformation of Health Care is met through the use of an excel spreadsheet 
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to track appointments made and kept or not kept for analysis, as well as the use of statistical 
software (IBM SPSS) to assist in that analysis to demonstrate significance. 
Essential V: Health Care Policy for Advocacy in Health Care was met through the 
preparation and presentation of a health policy brief poster on the cost of Hep C at the WV Nurse 
Policy Day in Charleston, WV in 2019, and by presenting the project in poster form at the 2020 
Nurse Policy Day.  
Essential VI: Interprofessional Collaboration for Improving Patient and Population Health 
Outcomes is being met through interprofessional collaborations with HCV experts (infectious 
disease expert NPs and physicians), social workers attuned to the unique needs of this 
population, and others through personal communication, online interaction via Project ECHO 
(Expanding Capacity for Health Outcomes), and participation in the West Virginia Hepatitis 
Academic Partners (WVHAMP) project as both a presenter and participant to advance primary 
care providers as expert (and unrestricted) HCV treatment prescribers.  
Essential VII: Clinical Prevention and Population Health for Improving the Nation’s 
Health is met through integrating a Hep C clinic to coincide with a harm reduction program with 
the intent of promoting engagement in care for hep C  which will increase the number of persons 
cured of this disease and reduce the risk of transmission.  
Essential VIII: Advanced Nursing Practice was met through creating new patient and 
professional relationships that promoted placement of the integrated clinic to improve patient 
outcomes. Establishing this clinic required thinking at a higher level in order to develop the 
protocols and systems that make the clinic function in a way that best meets the needs of the 
patients and organization.  
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Table 1.  
Implementation/Feasibility Survey Results    Descriptive statistics 
 n Minimum Maximum Mean 
Std. 
Deviation 
The HCV clinic fits well with the 
mission of MPHR 
13 1 1 1.00 0.000 
There is a need for an HCV clinic at 
MPHR 
13 1 1 1.00 0.000 
The HCV clinic at MPHR interferes 
with other services offered here 
13 4 6 5.00 0.408 
The transition to having an HCV 
clinic located at MPHR has been a 
smooth one 
13 1 3 1.46 0.660 
There is no need for an HCV clinic at 
MPHR 
13 5 5 5.00 0.000 
The HCV clinic is an added burden to 
the staff 
13 3 6 4.85 0.689 
I have or plan to refer patients to the 
HCV clinic at MPHR 
13 1 6 1.54 1.450 
The education program provided 
before the HCV clinic opened helped 
me understand the need for it at 
MPHR 
13 1 6 2.77 2.315 
The HCV clinic has increased 
congestion in the waiting room 
13 3 6 4.92 0.641 
The HCV clinic is valuable to MPHR 13 1 2 1.08 0.277 
The education program provided 
before the HCV clinic opened helped 
prepare me for my role 
15 1 6 3.13 2.200 
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Table 2. 
Percent of No-call/No-show       
   
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid Yes 2 40.0 40.0 40.0 
No 3 60.0 60.0 100.0 
Total 5 100.0 100.0 
 
INTEGRATING CARE   34 
 
Figure 1.  
Percent of No-call/No-show  
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Appendix A 
Hepatitis C Clinic at Milan Puskar Health Right Interview Questionnaire Survey Tool 
 
Patient age:                                               Gender (Circle one)    Male             Female 
Marital status (Circle one)      M       S       W      D 
Length of time since you were first diagnosed with Hep C? 
 
 
Employed          Yes            No 
1. Have you ever been referred to a Hepatitis C clinic in the past?          Yes            No            
2. If so, did you make that appointment?          Yes            No            
3. If you made an appointment, did you keep it?          Yes            No            
4. Below is a list of possible reasons you did not make or were not able to go to your appointment. 
For each problem listed please indicate on a scale of 1-5 how significant that was to missing your 
appointment. 1=Not at all; 2=a little; 3=moderately; 4=more; 5=a lot 
Transportation problems 1        2        3       4       5   
Forgot 1        2        3       4       5   
No insurance 1        2        3       4       5   
Copay was too high 1        2        3       4       5   
Insurance problems 1        2        3       4       5   
Sick on day of appointment  1        2        3       4       5   
Fear 1        2        3       4       5   
Childcare problems 1        2        3       4       5   
Work 1        2        3       4       5   
School  1        2        3       4       5   
Thought it was a waste of time 1        2        3       4       5   
Not satisfied with previous care/treatment 1        2        3       4       5   
Language or accessibility needs not met  1        2        3       4       5   
You heard from someone else there was nothing that could be done? 1        2        3       4       5   
Felt judged or discriminated against 1        2        3       4       5   
Other:   
5. What, if anything, could the healthcare system do to help you keep appointment/s at this clinic 
and any others you may have missed appointments at? 
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Appendix B 
Hep C Clinic at Milan Puskar Health Right Log of Appointment Responses  
Name (Delete name upon log entry of  
Appt Date/Time 
Appt 
Kept  
Called 
to 
cancel 
Called to 
reschedule 
No-
call/No-
show appointment outcome) 
Deleted 1/17/2020   x     
Deleted 
2/14/2020       x 
Deleted 2/14/2020       x 
Deleted 2/21/2020       x 
Deleted 2/28/2020 x       
Deleted 3/6/2020       x 
Deleted 3/13/2020 x       
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Appendix C 
 
INTEGRATING CARE   38 
 
Appendix D 
HCV Patient Labs/Studies Checklist 
Note: This is a list of what is standard for new HCV patient evaluation (it’s the checklist I use). 
With the removal of the liver fibrosis restriction imposed by Medicaid, we usually will not need a 
Fibrosure test or ultrasound, unless the patient has RUQ pain, jaundice, significantly elevated 
liver enzymes, or other s/s of liver damage.  
 
1. Confirm infection status with PCR RNA Quantitative with reflex to genotype 
 
Once infection status is confirmed – IF patient is being seen by PCP and getting 
labs prior to HCV Clinic, it would be great if these could be included. Otherwise, 
I will order at time of visit. 
 
2. Other pre-treatment labs (lipids and Fibrosure are 8-hour fasting labs): 
a. CBC/diff 
b. BUN/Cr 
c. AST, ALT, Alk phos 
d. Iron, Transferrin, Ferritin, and TIBC 
e. Total and calculated bili 
f. Albumin 
g. PTT, PT/INR (Check with Emily) 
h. Vitamin D 
i. HCV Genotype (if not already done) 
j. Liver Fibrosis (Fibrosure) Ask – may not be necessary for all patients 
Ruby:  1237128 (8 hour fasting) 
Mon Gen (LabCorp): 550123 (8 hour fasting)  
k. Anti-Hep A IGG, Hep A IgM Ab 
l. Hep B Surface Ab, Hep B surface antigen, Hep B total core Ab (Anti-HBc) – this 
is important to confirm no active Hep B infection – HCV treatment can cause a 
flareup of symptoms 
m. A1C 
n. Consider lipid panel  
3. Imaging – Elastography (CPT = 91200)     OR     RUQ US (CPT = 76705) as needed 
4. PHQ9 Patient Health Questionnaire tool for depression   
5. Assess for and immunize as appropriate for: 
a. Hep A  
b. Hep B 
c. Pneumovax  
d. Tdap 
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Appendix E 
Budget 
Clinic Items Projected Cost 
Actual 
Cost 
Difference 
Administrative: Nurse Practitioner (Project Coordinator) time = 
$50/hr x 4hrs/week x 12 weeks = $2400 clinical time, $50/hour 
x 10 hours for preparation of materials, staff education  
Support staff cost absorbed by organization (no additional staff 
required at this time) 
$2900  $2900 $0 
Educational Materials (Flyers for patients, Ppt handouts for 
staff, CE/certificate) 
$50 $10 +$40 
Project supplies (Office supplies, copy paper) $25 $10 +$15 
Facilities (Contributed by organization) $0 $0 $0 
Hospitality (Lunch for 10 staff on education day X  $15/pp) $150  $123 +$27 
Travel (N/A – travel is within author’s normal driving distance) $0  $0 $0 
Incentive (small token for questionnaire completion by known 
HCV positive patients - $2/each for 50 questionnaires) 
$100  $25 +$75 
Unanticipated expenses $50  $0 +$50 
Marketing (Flyers to post in clinic-cost covered under supplies) $0  $0 $0 
Total $3,275  $3068 +$207 
Projected Income Source Amount 
WVCTSI Small Grant $5,000  
Personal funds $200  
Other $0  
Total projected income       $5,200 
Total actual income                         $3100 
Total actual cost                            - $3068 
                          +$32 
  
       Additional budget comments:  
• MPHR is funded by grants and donations. Hourly wage based 
on the US Bureau of Labor and Statistics average NP wage for 
West Virginia (U.S. Bureau of Labor Statistics, 2018) 
• Patient gifts were purchased as appreciation for completing a  
questionnaire.  
• Facilities are already operational with all necessary equipment 
and software. Student will use personal computer equipped 
with Excel to create and maintain deidentified tracking log 
• This location already has clinics servicing patients, a 
concurrent 4-hour clinic should not add an undue burden to 
current staff 
• Met with WVCTSI staff member on 7/16/19 – was encouraged 
to apply for a grant; however, the time frame to apply for a 
grant to use in the projected time frame for this project had 
passed. Time and money donated by author kept cost within 
budget. 
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Appendix F 
Milan Puskar Health Right Hepatitis C Clinic – Getting started checklist 
 
 
 Meet with key leaders and sign agreement with Milan Puskar Health Right 
 Start credentialing with MPHR 
 Copy of malpractice insurance from Toni Dichiacchio 
 CAQH ProView Updated and attested  
 Notify WVBON - Prescribing  
 Education/in-service with MPHR staff 
Review paperwork – checklists, phone triage, intake form   
 DNP Student to orient to MPHR EHR System 
 DNP Student to orient to workflow at MPHR 
 Set up exam room (exam table, chair, otoscope, reflex hammer, tongue blades) 
 Set up desk space (office supplies as needed) 
   
  
 
= Completed prior to January 17, 2020 – the first day of clinic 
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Appendix G 
Staff Education Pre and Post Test 
1. Hepatitis C is a systemic disease?      True      False 
2. A DAA is: 
 a. A direct acting antiviral 
 b. A direct antiviral agent 
 c. A decreased antiviral account 
 d. None of the above 
3. Drug manufacturers do not provide medications to needy patients.  True  False 
4. When patients call to ask questions about the Hepatitis C/clinic I should.... 
 a.  Tell them, “I can’t answer any questions” and they should just make an appointment 
 b.  Refer to the Phone Triage form to find answers to the most common questions 
 c. Tell the patient I don’t know the answer but I can find out and get back to them 
 d. b and c 
5. The new patient intake questionnaire- 
 a. is for patients who already come to Milan Puskar Health Right for their primary care 
 b. is for all patients who are being seen in the Hepatitis C clinic for the first time 
 c. does not need completed if patient is already established at Milan Puskar Health Right 
 d. must be completed by a nurse 
6. Medicaid does not cover treatment for Hepatitis C   True  False 
7. Prior authorization can be obtained by – select all that apply 
 a. a nurse practitioner  
 b. a medical assistant (MA) 
 c. an LPN 
 d. specialty pharmacy  
 e. all of the above 
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Appendix H 
   Staff Satisfaction Questionnaire (Anonymous) 
Comments: 
 
What would improve your confidence in managing HCV patients at MPHR? 
 
  
Please circle your response: 
 1=Very satisfied 2=Satisfied 3=Neutral 4=Dissatisfied 5=Very dissatisfied 
The educational program helped me feel prepared for this clinic. 
1 2 3 4 5 
 
The Phone Triage flyer helped me answer questions when patients called. 
1 2 3 4 5 
 
The education program helped me feel more confident about using patient 
assistance programs for HCV medications 
1 2 3 4 5 
 
 The learning objectives (disease process, fielding phone question, anticipated 
lab and imaging tests, assistance programs) were met  
1 2 3 4 5 
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Appendix I 
Hepatitis C Clinic at Milan Puskar Health Right Implementation/Feasibility Survey Tool 
 
Demographic information:                                          
Gender(Circle one)  Male  Female  Prefer not to answer                 Age:__________Years 
Length of time employed at Health Right (if paid employee): __________Years  
Employment status:                                    Full time               Part time 
Volunteer at Health Right                          Number of hours/week___________ 
Role/position at Health Right (Nurse, provider, case manager, etc…) ________________________ 
Did you attend the Lunch and Learn educational program in January? 
         Yes            No 
Please rate your response to each question on the topic of having a hepatitis C (HCV) clinic located at 
Milan Puskar Health Right (MPHR) using the following scale: 
 
1=Strongly Disagree; 2=Disagree; 3=Neutral; 4=Agree; 5=Strongly Agree 
The HCV clinic fits well with the mission of MPHR N/A   1       2        3       4       5   
There is a need for an HCV clinic at MPHR N/A   1       2        3       4       5   
The HCV clinic at MPHR interferes with other services offered here N/A   1       2        3       4       5   
The transition to having an HCV clinic located at MPHR has been a 
smooth one 
N/A   1       2        3       4       5   
There is no need for an HCV clinic at MPHR N/A   1       2        3       4       5   
The HCV clinic is an added burden to the staff  N/A   1       2        3       4       5   
I understand the process of referring to the HCV clinic at MPHR N/A   1       2        3       4       5   
I have or plan to refer patients to the HCV clinic at MPHR 
N/A   1       2        3       4       5   
The education program provided before the HCV clinic opened helped 
me understand the need for it at MPHR 
N/A   1       2        3       4       5   
The HCV clinic increased congestion in the waiting room N/A   1       2        3       4       5   
The HCV clinic is valuable to MPHR N/A   1       2        3       4       5   
The education program provided before the HCV clinic opened helped 
prepare me for my role 
N/A   1       2        3       4       5   
Other suggestions or comments:  
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Appendix J 
 
 
From: Danielle Ludwig <dani.ludwig.light@gmail.com> 
Sent: Friday, April 10, 2020 1:54 PM 
To: McKenrick, Susan <susan.mckenrick@hsc.wvu.edu> 
Subject: Re: Question for you 
  
Just reading that made my heart melt and tears to my eyes! You just don’t know how 
grateful I am for you! Thanks for adding me to your project! The love I have for you is 
unconditional and true.  
 
Much love my dear friend, 
Dani 
 
On Thu, Apr 9, 2020 at 5:48 PM McKenrick, Susan <susan.mckenrick@hsc.wvu.edu> 
wrote: 
Hi Dani, 
 
I will be presenting my DNP project next week and I am finally finishing up my paper. Below is 
my acknowledgment page - I wanted to share it with you and make sure you are OK with your 
name being in it.  
 
Hugs, 
 
Sue 
 
Susan R. McKenrick, MSN, APRN, FNP-BC, DNP2B 
Clinical Assistant Professor 
WVU School of Nursing 
6600 Health Sciences Center 
Post Office Box 9600 
Morgantown, WV  26506-9602 
susan.mckenrick@hsc.wvu.edu 
  
 
 
